Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: from risk factors to disease modulators by BORRONI B et al.
Neurobiology of Aging 25 (2004) 747–751
Intronic CYP46 polymorphism along with ApoE genotype in sporadic
Alzheimer Disease: from risk factors to disease modulators
Barbara Borroni a, Silvana Archetti b, Chiara Agosti a, Nabil Akkawi a, Cristina Brambilla a,
Luigi Caimi c, Carlo Caltagirone d, Monica Di Luca e, Alessandro Padovani a,∗
a Neurologic Clinic, University of Brescia, Spedali Civili de Brescia, Piazzale Spedali Civili 1, Brescia 25123, Italy
b III Laboratory of Analysis, University of Brescia, Brescia, Italy
c Department of Biotechnology, Biochemistry Unit, University of Brescia, Brescia, Italy
d Neurologic Clinic, IRCCS S. Lucia, University “Tor Vergata”, Rome, Italy
e Centre of Excellence for Neurodegenerative Diseases, Institute of Pharmacological Sciences, University of Milan, Milan, Italy
Received 17 June 2003; accepted 26 August 2003
Abstract
Increasing biological and clinical findings argue for a link between brain cholesterol turnover and Alzheimer Disease (AD), high cerebral
levels of the former increasing A load. Cerebral cholesterol elimination involves two mechanisms dependent on Apolipoprotein E (ApoE)
and cholesterol 24-hydroxylase (CYP46).
The aim of this study was to evaluate an intronic variation in CYP46 (intron 2, T → C) along with ApoE genotype as risk factors for AD
and to establish the correlation between CYP46/ApoE polymorphism and disease progression. One-hundred and fifty-seven AD patients,
who had been followed periodically through 1-year follow-up after enrolment, and 134 age- and gender-matched controls entered the study.
The distribution of CYP46 genotypes was significantly different in AD compared to controls (P < 0.004), being CYP∗C allele higher
in AD patients (P < 0.002). ApoE ε4 genotype was more frequent in AD (41.4%) than in controls (15.9%, P < 0.0001). The odds ratio
(OR) for AD risk in CYP46∗C carriers was 2.8, and in ApoE ε4 carriers was 4.05; the OR for having both CYP46∗C and ApoE ε4 was
17.75, demonstrating the their synergic effect on AD risk. In AD patients, CYP46∗C along with ApoE ε4 genotype were associated with
a higher cognitive decline at 1-year follow-up (P < 0.02).
These findings provide direct evidence that CYP46 and ApoE polymorphisms synergically increase the risk for AD development, and
influence on the rate of cognitive decline.
© 2003 Elsevier Inc. All rights reserved.
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1. Introduction
There is growing interest in the potential contribution of
cholesterol in the pathogenesis of Alzheimer Disease (AD),
several evidences highlighting a role of hypercholestero-
laemia in increasing AD risk and worsening disease pro-
gression [3,12,19].
In fact, pre-clinical studies have shown an association be-
tween elevated mid-life serum total cholesterol levels and
late-life AD, and a reduced incidence rate of the disease has
been observed in subjects treated with statins, thus suggest-
ing that cholesterol-lowering drugs may exert a protective
role on AD onset [6–9]. Linkage between cholesterol and
AD had also been suggested by the main recognised genetic
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risk factor for sporadic late-onset AD, i.e. Apolipoprotein E
(ApoE), which is involved in cholesterol homeostasis [18].
In fact, a wide body of data demonstrated that ApoE ε4 car-
riers are at greater risk of developing AD [22].
Further, it has been demonstrated that cholesterol affects
the pathogenic mechanisms of the disease, modulating the
amyloid precursor protein (APP) processing, being high
cholesterol levels a factor increasing A biogenesis and A
toxicity [2,15,20,21].
All together literature findings claim that the excess of
brain cholesterol, which is locally synthesised, needs to
be eliminated. The blood–brain barrier prevents cholesterol
transport from the brain to the blood, thus elimination path-
ways are necessary [10]. Cholesterol leaves the brain by two
different mechanisms: one is ApoE-dependent, ε4 allele be-
ing less effective in this process, while the second involves a
recently cloned gene cholesterol 24S-hydroxylase (CYP46)
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[11,24]. CYP46 is an enzyme almost exclusively located
in the brain and catalyses the conversion of excess choles-
terol into 24S-hydroxycholesterol, which is readily secreted
across the blood–brain barrier into the circulation [11]. A
putative functional role of CYP46 has been postulated: an
increase of 24-hydroxycholesterol in cerebrospinal fluid of
AD patients has been shown, and different groups have anal-
ysed an intronic variation of CYP46, since genetic polymor-
phisms might influence functionality of the corresponding
protein, but with contrasting results [5,10,16,17].
These observations, arguing for a key-role of genes in-
volved in cholesterol turnover in AD, provide the rationale
of the present study, aimed to evaluate an intronic variation
in CYP46 (intron 2, T → C) along with ApoE genotype, as
risk factors and disease modulators in AD.
2. Materials and methods
2.1. Subjects
Patients consecutively admitted at the “Centre of Age-
ing Brain and Neurodegenerative Disorders”, University of
Brescia, Italy, entered the study. All patients performed a
somatic and neurological examination, laboratory analysis,
ApoE and CYP46 genotyping, and brain imaging study
(Computed Tomography or Magnetic Resonance Imaging).
A wide standardised multidimensional assessment evaluat-
ing global cognitive functions and behavioural disturbances
was performed in each subject.
A diagnosis of probable AD was based on National In-
stitute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Associ-
ation (NINCDS-ADRDA) criteria [13].
The following exclusionary criteria for the AD group
were designed to ensure that participants had probable AD
as the cause of their dementia: (a) major depressive disorder,
bipolar disorder, schizophrenia, substance use disorder, or
mental retardation according to criteria of the DSM-IV; (b)
cerebrovascular disorders, hydrocephalus, and intra-cranial
mass, documented by CT or MRI within the past 12 months;
(c) abnormalities in serum folate and Vitamin B12, syphilis
serology, or thyroid hormones’ levels; (d) a history of trau-
matic brain injury or another neurologic disease (e.g. Parkin-
son disease, Huntington disease, seizure disorders); (e)
significant medical problems (e.g. poorly controlled diabetes
or hypertension; cancer within the past 5 years; clinically
significant hepatic, renal, cardiac or pulmonary disorders).
Moreover, an age- and gender-matched control sample
from the same Italian area from which the patients were
drawn was recruited. All controls were found to be cogni-
tively intact, following medical history and neuropsycholog-
ical examination.
The study was conducted in accordance with local clinical
research regulations and an informed consent was required
from all subjects and caregivers when indicated.
Polymorphism analyses were performed blinded to diag-
nosis and genotype.
2.2. CYP46 genotype
Genomic DNA was isolated from whole blood samples
by extraction using a salting procedure.
A 285 bp polymerase chain reaction (PCR) product con-
taining CYP46 was amplified using specific primers (for-
ward primer: 5′-TGA AAA CGA GTT TCC CGT CC-3′;
reverse primer: 5′-GTG TGA CCA GGT AAC AGT CA-3′).
PCR was performed using 100 ng of genomic DNA in 50 ml
of reaction mixture.
After initial denaturation at 95 ◦C for 5 min, reaction mix-
ture was subjected to 32 cycles of 30 s denaturation at 95 ◦C,
30 s annealing at 53 ◦C, and 30 s extension at 72 ◦C, fol-
lowed by 10 min extension step at 72 ◦C. PCR products were
digested by MspI restriction enzyme. CYP46 T allele cor-
responded to the uncut 285 bp fragment, while CYP46 C
allele was characterised by two fragments of 209 and 76 bp.
The results of amplification and the digestion fragments
were revealed by 2 and 3% agarose gels with ethidium bro-
mide, respectively.
2.3. ApoE genotyping
Genetic variation at the ApoE locus is determined by re-
striction isotyping using PCR amplification and subsequent
digestion with HhaI (New England Biolabs). The nucleotide
substitutions that result in Arg–Cys interchange at position
112 and 158 alter HhaI cleavage sites: each genotype can
be distinguished by unique combinations of HhaI fragment
sizes in all homozygotic and heterozygotic combinations.
2.4. Study design
AD patients and healthy controls were evaluated at base-
line and a blood venipuncture for DNA extraction and
polymorphisms’ analysis was performed. In regard to AD
patients, current available therapy with Cholinesterase In-
hibitors (ChEIs) had been administered at recommended
dosage, and they had been followed periodically, and
1-month and 1-year follow-up neuropsychological assess-
ment was recorded.
2.5. Statistical methods
Genotype and allele frequencies between AD patients
and control subjects were compared by Pearson χ2 test.
Hardy–Weinberg equilibrium of the examined population
was confirmed by χ2 test.
For all the continuous variables, the analysis of varia-
tions between groups was performed using the unadjusted
ANOVA. In order to account for possible confounds (gen-
der, age), the ANCOVA has been performed as well. Fur-
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Table 1
CYP46 and ApoE in AD patients and in controls
Controls
(n = 134)a
AD
(n = 157)a
Pb
CYP46 (intron 2, T → C) genotype % (n)
TT 64.2 (86) 45.4 (65)
TC 28.3 (38) 47.6 (68)
CC 7.5 (10) 7.0 (10) 0.004
TT 64.2 (86) 45.4 (65)
CT or CC 35.8 (48) 54.6 (78) <0.0001
ApoE genotype % (n)
ε4 15.8 (20) 41.4 (65)
Non-ε4 84.2 (107) 58.6 (92) <0.0001
ε2 allele frequency 3.6 (9) 2.5 (8)
ε3 allele frequency 88.5 (225) 74.8 (235)
ε4 allele frequency 7.9 (20) 22.6 (71) <0.0001
a Difference on the totals are due to missing data.
b Pearson χ2 test.
ther analysis was carried out by using ANOVA for repeated
measures. Statistical significance was assumed at P < 0.05.
The analysis was performed using the software STATA®
7.0 (Intercooled Stata 7.0 for Windows, Stata Corporation,
College Station, TX).
3. Results
One hundred and fifty-seven demented patients (female:
61.8%; age: 72.2± 7.9), and 134 age- and gender-matched
control subjects entered the study.
The distribution of CYP46 genotypes was significantly
different in AD compared to controls (P = 0.004; see
Table 1). The presence of at least one of ∗C allele (CYP46∗C:
CYP46 C/T or CYP C/C) was higher in AD patients (54.6%)
compared to control subjects (35.8%, P < 0.0001).
The distribution of ApoE isoforms significantly differed
between AD cases and controls, being ApoE ε4 genotype
more frequent in patients (AD versus controls: 41.4% versus
15.8%, P < 0.0001). The presence of at least one ApoE
Table 2
Demographic and clinical characteristics of AD patients who completed 1-year follow-up according to CYP46 and ApoE genotypea
Variable CYP46∗non-C ApoE∗non-4 CYP46∗non-C ApoE∗4 CYP46∗C ApoE∗non-4 CYP46∗C ApoE∗4 Pb
n 21 21 32 18 –
Age (year) 72.3 ± 7.7 73.2 ± 5.5 69.8 ± 10.5 72.5 ± 5.5 0.45
Gender, F/M 11/10 14/7 18/15 13/5 0.50c
MMSE baseline 20.1 ± 5.8 19.7 ± 6.0 19.3 ± 6.3 20.4 ± 5.1 0.94
MMSE 1-month 20.6 ± 5.8 19.9 ± 5.8 19.7 ± 6.0 20.8 ± 5.0 0.96
MMSE 1-year 19.8 ± 5.6 18.9 ± 6.4 18.5 ± 6.5 17.9 ± 6.4 0.84
MMSE −0.33 ± 2.6 −0.80 ± 2.2 −0.81 ± 2.3 −2.5 ± 3.3 0.06
MMSE: Mini-Mental State Examination; MMSE: MMSE 1-year−MMSE baseline CYP46∗non-C: CYP46 TT; CYP46∗C: CYP46 TC or CYP46 CC;
ApoE∗non-4: ApoE ε2/ε2 or ApoE ε3/ε3 or ApoE ε3/ε2 or ApoE ε2/ε2; ApoE∗4: ApoE ε3/ε4 or ApoE ε4/ε4.
aMean (±S.D.).
bUnadjusted ANOVA.
cPearson χ2 test.
ε4 allele (ApoE∗4) was significantly associated with AD
(AD versus controls: 22.6% versus 7.9%, P < 0.0001; see
Table 1).
Crude OR for the risk of AD in CYP46∗C carriers was
2.56 (95% confidence interval: 1.58 to 4.08), while for
ApoE∗4 carriers it was 3.78 (95% CI: 2.13 to 6.71). Com-
pared to subjects with neither CYP46∗C nor ApoE∗4, the
OR for the presence of CYP46∗C without ApoE∗4 allele
was 2.81 (95% CI: 1.60 to 4.97), the OR for the presence of
ApoE∗4 allele without CYP46∗C was 4.05 (95% CI: 1.95
to 8.39); the OR for having both CYP46∗C and ApoE∗4
was 17.75 (95% CI: 5.83 to 54.06), demonstrating their
synergic effect on AD risk.
Eighty-eight patients completed the 1-year follow-up and
were re-evaluated. Only patients who have never experi-
enced ChEIs treatment before enrolment were considered at
follow-up, to avoid confounds. These patients were grouped
according to ApoE and CYP46 genotype. As shown in
Table 2, ApoE∗4/CYP46∗C grouped patients, who com-
pleted 1-year follow-up, did not differ for demographic or
clinical characteristics.
Rate of cognitive decline was calculated as MMSE
(MMSE 1 year − MMSE baseline), and factors related
to MMSE analysed. Adjusting for age and gender, nor
ApoE∗4 genotype, nor CYP46∗C genotype, but the com-
bination ApoE ε4/CYP46∗C predicted MMSE (P =
0.0454). In fact, at 1-year follow-up AD patients carry-
ing both ApoE ε4 and CYP∗C polymorphisms showed a
higher rate of cognitive decline compared to the others
(F [2, 168] = 2.62, P < 0.02), while no differences among
groups were found at 1-month follow-up (see Table 2, and
Fig. 1).
4. Discussion
It is well established that sporadic late-onset AD is a
polygenic disease, several genetic polymorphisms being
suggested as modulators of AD susceptibility [4]. Among
others, several proposed genes encode for protein that are
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Fig. 1. Changes in MMSE scores at 1-month and 1-year follow-up in AD patients according to CYP46 and ApoE polymorphisms. ,
ApoE∗4/CYP46∗C; , ApoE∗non-4/CYP46∗C; , ApoE∗4/CYP∗non-C; , ApoE∗non-4/CYP∗non-C. MMSE: Mini-Mental State Examination
(MMSE) follow-up − MMSE baseline. CYP46∗non-C: CYP46 TT; CYP46∗C: CYP46 TC or CYP46 CC; ApoE∗non-4: ApoE ε2/ε2 or ApoE ε3/ε3 or
ApoE ε3/ε2; or ApoE∗4: ApoE ε3/ε4 or ApoE ε4/ε4.
involved in lipid homeostasis, thus claiming that cholesterol
plays a key-role in AD pathogenesis [1].
In this study, we reported that an intronic variation in
CYP46, CYP46∗C, along with ApoE ε4 genotype sinergi-
cally increase the risk of AD development; further, AD pa-
tients carrying the combination of these two polymorphisms
showed a higher rate of cognitive decline at 1-year follow-up.
CYP46 and ApoE are involved in the pathways by which
excess brain cholesterol is transported into circulation [10].
Biological evidences have strengthened the role of these two
proteins in AD. In fact, it is well established that ApoE in-
duces cholesterol efflux in an isoform-dependent manner, as
the most recognised sporadic AD-related risk factor ε4 al-
lele appears to be less effective in this process [14]. Further,
it has been demonstrated that AD is characterised by abnor-
mal induction of CYP46 enzyme, which leads to changes
in 24S-hydroxycholesterol from brain to circulation [17,23].
Neuropathological evidences reported that high concentra-
tion of CYP46 has been found in glial cells in AD brains,
suggesting that an imbalance of cholesterol turnover may be
a feature of reactive astroglia in the disease [4].
How CYP46 polymorphisms, such as intronic variation
here reported, affect protein function has not been estab-
lished yet. It could be speculated that intronic variations can
either influence on the rate of transcription of gene products
by affecting splice sites or modulate nuclear trascriptional
factors.
According to this, an imbalance of cholesterol turnover,
due to less effective physiological mechanisms, such as that
determined by ApoE or CYP46 genetic variations, could
represent a risk factor for AD development, and could
worsen disease progression once symptomathology is overt.
In agreement, AD patients carrying both CYP46∗C and
ApoE∗4 progressed much more faster at 1-year evaluation.
We acknowledge that our study has some limitations.
First of all, a wider sample of subjects is needed as
well as hypothesis-confirming sample from other coun-
tries. Secondly, further biological studies analysing CYP46
polymorphisms’s effect on cholesterol metabolism are
mandatory.
Despite these limitations, this study underlines once
more the importance of taking into account the enzymatic
pathways which are involved in cholesterol homeostasis to
better understand how they influence on AD development.
The complex interplay between genetic and environmen-
tal factors should be introduced into future trials to fully
appreciate individual susceptibility and prognosis’ determi-
nants in AD. In fact, the present findings argue for a double
implication of CYP46 and ApoE genotyping, since these
genes act both as risk factors and disease modulators in AD.
Establishing the real impact of the intricate maze of these
genetic polymorphisms and corresponding proteins’ func-
tion represents a key-issue in the progress of the pathology’s
knowledge, leading to a better definition of the disease and
providing many potential opportunities to design preventive
therapeutic strategies.
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